Vendor Intelligence Report: Shandong Aishi Biotechnology
Published 12 Nov 2026. 32-page investigative report on who is behind Shandong Aishi Biotechnology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Shandong Aishi is not a simple good-vendor/bad-vendor case. Across 90 Finnrick lab tests, the overall record is 72 pass / 18 fail, an 80% pass rate. The dispersion matters more than the headline: GHK-Cu is the clearest positive signal, Tirzepatide and Retatrutide sit in a cautious middle, and Tesamorelin is the weak product that changes the buying posture. The report also shows why ratings fall under stricter grading when dosing precision matters.
The company itself is real, but the factory story remains thinly verified. Chinese registry and SGS-linked records tie the operation to Shandong Aishi Biotechnology Co., Ltd. and Zhang Yiguo, while marketplace and website claims describe production lines, clean workshops, ISO/GMP manufacturing and sizable staffing. The public records reviewed did not identify a named QA lead, technical director, batch-release signatory, licence record or certificate number that resolves those claims.
The channel picture is the stronger hook. The listed shandongaishi.com domain is non-functional in the investigation record, while four Aishi-branded replacement domains launched in a tight July 2026 cluster with shared templates, product codes and COAs but different Gmail and +852 contact pairs. A separate near-name peptide shop is not evidenced as Aishi, creating a practical typo and reseller-authentication risk.
Aishi’s vendor-published Janoshik reports are useful identity evidence, not release certificates. The same COA set appears across multiple domains under one shared submission batch, with high-purity sample results but no public vial-level lot matching, sterility, endotoxin, expiry or production-site audit evidence.
Inside the full report:
- Per-product pass/fail rates, rating trajectories and methodology-divergence charts for all 7 products
- Corporate registry, SGS Global Sources and GuideChem records reconciled against Aishi’s manufacturing claims
- Domain-rotation analysis of the dead legacy site and four July 2026 Aishi-branded funnels
- COA traceability review of the shared Janoshik batch, verification-key limitations and overfill patterns
- Channel-authentication map covering emails, +852 numbers, Facebook/TikTok surfaces, Google Ads tags and the near-name domain
- Risk matrix separating GHK-Cu, GLP-1s and weak products from corporate, licensing and supply-chain risks
Risk assessment
- Dosing/quality risk — Tesamorelin and HGH — high: Tesamorelin is 7 tests, 3 pass / 4 fail, 46.37%; HGH is 3 tests, 1 pass / 2 fail, 38.44%; prefer another vendor or independently test the exact batch.
- Dosing/quality risk — BPC-157 — medium: BPC-157 has 3 tests, 3 pass / 0 fail, but only a 56.04% Finnrick rating and a very small sample; do not read the all-pass count as a strong signal.
- Dosing/quality risk — Retatrutide and Tirzepatide — medium: Retatrutide is 26 tests, 20 pass / 6 fail, 75.7%; Tirzepatide is 31 tests, 25 pass / 6 fail, 80.91%; both require current-batch verification.
- Unverified manufacturing and licensing claims — high: Claims of five production lines, 500+ varieties, ISO/GMP manufacturing and 100–149 employees conflict with Qichacha’s 0 insured employees, 0 administrative licences and 0 qualification certificates.
- Channel/domain authentication and copycat risk — high: The listed shandongaishi.com domain is non-functional; four Aishi domains use different contacts; no official-channel or reseller list is published; aspeptide.com is a different near-name vendor.
- Batch traceability and injectable-safety evidence risk — medium: Published COAs share batch AS20260623 and lack vial-level lot matching, production lot, expiry, sterility or endotoxin data; a COA cannot be tied to a specific vial from public documents alone.
- Corporate and enforcement transparency risk — medium: One-person LLC formed 2025-04-29 with Zhang Yiguo in all formal roles; Qichacha records 2 administrative penalties with unresolved details and only 1 annual report.
- Upstream-source and dual-use catalog risk — medium: No upstream peptide manufacturer was identified; GuideChem ties the same entity to broader chemical/API listings including 4-methylpropiophenone, supporting a trader/intermediary posture.